Compared with patients who had a medium platelet count, patients with a very high platelet count had more than double the risk of a solid tumor diagnosis.
Early treatment discontinuation was associated with a decrease in survival, but early oxaliplatin discontinuation was not.
Melflufen prolonged progression-free survival when compared with pomalidomide.
The risk of hypertension was even higher for those receiving left-sided radiation or endocrine therapy.
The global burden of CLL increased from 40,537 cases in 1990 to 103,467 in 2019.
The government’s order for the free test kits is in addition to the existing supply and does not interfere with existing orders.
Adding durvalumab to gemcitabine and cisplatin improved progression-free and overall survival.
The median overall survival was 7.5 months in the eryaspase arm and 6.7 months in the chemotherapy-alone arm.
The median overall survival was 16.4 months with STRIDE and 13.8 months with sorafenib.
TACE improved responses and survival outcomes.